Novocure Ltd (NVCR)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.38B
Last updated: Nov 17, 2026 at 11:06 AM ET
Novocure Ltd (NVCR) Stock Forecast
Analysts expect Novocure (NVCR) to earn -$1.05 per share in the fiscal year ending Dec 31, 2026, on revenue of $740.20M. Of 7 analysts, 4 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.29, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 57% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 14.3% |
| Buy | 3 | 42.9% |
| Hold | 3 | 42.9% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 9.3%.
- Fiscal year ending Dec 31, 2026
- -$1.05
- EPS consensus, revenue $740.20M
- Fiscal year ending Dec 31, 2027
- -$0.73
- EPS consensus, revenue $809.26M
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.05 | -$1.09 to -$1.03 | 6 | $740.20M | $737.13M to $742.30M | 6 |
| Dec 31, 2027 | -$0.73 | -$1.06 to -$0.22 | 7 | $809.26M | $783.90M to $855.99M | 7 |
Quarterly Estimates
The EPS consensus rises from -$0.24 for the quarter ending Dec 31, 2026 to -$0.20 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.24 | -$0.30 to -$0.20 | 9 | $193.67M | $183.24M to $200.88M | 9 |
| Mar 31, 2027 | -$0.20 | -$0.25 to -$0.13 | 4 | $189.43M | $184.80M to $192.80M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 6 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 4 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.25.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.05 | -$1.05 | -$1.24 | -$1.25 | -$1.25 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.73 | -$0.72 | -$0.81 | -$0.82 | -$0.82 | N/A |
| Quarter ending Mar 31, 2027 | -$0.20 | -$0.19 | -$0.22 | -$0.22 | -$0.22 | N/A |
Frequently Asked Questions About NVCR
What is the NVCR stock forecast?
Consensus analyst estimates put Novocure's EPS at -$1.05 for the fiscal year ending Dec 31, 2026, on revenue of $740.20M. The consensus rating from 7 analysts is Buy.
How do analysts rate NVCR stock?
Of 7 analysts covering Novocure, 1 rates it Strong Buy, 3 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NVCR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.05, with estimates from -$1.09 to -$1.03 from 6 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.73, with estimates from -$1.06 to -$0.22 from 7 analysts.
What revenue do analysts expect from Novocure next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $740.20M, with estimates from $737.13M to $742.30M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $809.26M, with estimates from $783.90M to $855.99M.
How many analysts cover NVCR?
7 analysts rate Novocure stock, and 6 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
NVCR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts